{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:17:57Z","timestamp":1780337877491,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R34 HL108761"],"award-info":[{"award-number":["R34 HL108761"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01 HL128566"],"award-info":[{"award-number":["U01 HL128566"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01 HL128568"],"award-info":[{"award-number":["U01 HL128568"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtct.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T07:08:25Z","timestamp":1666076905000},"page":"217-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-0037","authenticated-orcid":false,"given":"Lakshmanan","family":"Krishnamurti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/jcm8101523","article-title":"Why, who, when, and how? Rationale for considering allogeneic stem cell transplantation in children with sickle cell disease","volume":"8","author":"Bernaudin","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.10.008_bib0003","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamapediatrics.2019.4715","article-title":"Familial haploidentical stem cell transplant in children and adolescents with high-risk sickle cell disease: a phase 2 clinical trial","volume":"174","author":"Cairo","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jtct.2022.10.008_bib0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.hemonc.2019.12.006","article-title":"Alternative donor: \u03b1\u00df\/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease","volume":"13","author":"Foell","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.008_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hemonc.2020.01.002","article-title":"Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: an update","volume":"13","author":"Patel","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.008_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2018.04.001","article-title":"Shared decision-making in hematopoietic stem cell transplantation for sickle cell disease","volume":"24","author":"Sullivan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.008_bib0009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0010","first-page":"27","article-title":"Availability of related donors for bone marrow transplantation in sickle cell anemia","volume":"16","author":"Mentzer","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.10.008_bib0011","series-title":"Prevalence of Sickle Cell Disease among Medicaid Beneficiaries in 2012","author":"Wilson-Frederick","year":"2019"},{"issue":"4 suppl","key":"10.1016\/j.jtct.2022.10.008_bib0012","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0013","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jtct.2021.01.022","article-title":"A qualitative analysis of state Medicaid coverage benefits for allogeneic hematopoietic cell transplantation (alloHCT) for patients with sickle cell disease (SCD)","volume":"27","author":"Mupfudze","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.008_bib0014","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJMp2022125","article-title":"When actions speak louder than words\u2014racism and sickle cell disease","volume":"383","author":"Power-Hays","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0015","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2101627","article-title":"A hidden opportunity\u2014Medicaid's role in supporting equitable access to clinical trials","volume":"384","author":"Takvorian","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2022.10.008_bib0016","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","article-title":"Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.10.008_bib0017","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/phar.2329","article-title":"Systematic review of l-glutamine for prevention of vaso-occlusive pain crisis in patients with sickle cell disease","volume":"39","author":"Cieri-Hutcherson","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtct.2022.10.008_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","article-title":"Voxelotor: First approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2022.10.008_bib0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: First approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2022.10.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6742","article-title":"Assessment of patient and caregiver attitudes and approaches to decision-making regarding bone marrow transplant for sickle cell disease: a qualitative study","volume":"3","author":"Bakshi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2022.10.008_bib0021","doi-asserted-by":"crossref","first-page":"e28749","DOI":"10.1002\/pbc.28749","article-title":"Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease","volume":"68","author":"Sinha","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.10.008_bib0022","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.008_bib0023","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1182\/blood.2020006020","article-title":"Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers","volume":"137","author":"Pittman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.008_bib0024","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pain.2009.06.029","article-title":"Pain site frequency and location in sickle cell disease: the PiSCES project","volume":"145","author":"McClish","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jtct.2022.10.008_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jtct.2022.10.008_bib0026","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jpain.2016.06.009","article-title":"United States National Pain Strategy for population research: concepts, definitions, and pilot data","volume":"17","author":"Von Korff","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.jtct.2022.10.008_bib0027","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5-year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.10.008_bib0028","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ymthe.2021.03.010","article-title":"A pause in gene therapy: reflecting on the unique challenges of sickle cell disease","volume":"29","author":"Leonard","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.10.008_bib0029","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.008_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.008_bib0031","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.008_bib0032","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.10.008_bib0033","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.008_bib0034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.008_bib0035","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.008_bib0036","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT Diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"J Pain"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T21:19:28Z","timestamp":1721683168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2666636722017031"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}